CY1107901T1 - Μεθοδος προσδιορισμου για ασθενεια alzheimer - Google Patents
Μεθοδος προσδιορισμου για ασθενεια alzheimerInfo
- Publication number
- CY1107901T1 CY1107901T1 CY20081100267T CY081100267T CY1107901T1 CY 1107901 T1 CY1107901 T1 CY 1107901T1 CY 20081100267 T CY20081100267 T CY 20081100267T CY 081100267 T CY081100267 T CY 081100267T CY 1107901 T1 CY1107901 T1 CY 1107901T1
- Authority
- CY
- Cyprus
- Prior art keywords
- beta
- alzheimer
- determination method
- preclinical
- disease
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Ένα διαγνωστικό τεστ για προκλινική και κλινική ασθένεια Alzheimer βασίζεται επί επιπέδων Αβ40, Αβ42 πλάσματος, αναλογίας αυτών ή του ρυθμού εισαγωγής αυτών μετά από χορήγηση αντισωμάτων που ρυθμίζουν Αβ. Μεταβολές οποιασδήποτε από αυτές τις παραμέτρους από τιμές αναφοράς πιστοποιούν προκλινική ή κλινική ασθένεια Alzheimer.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31322401P | 2001-08-17 | 2001-08-17 | |
US31322101P | 2001-08-17 | 2001-08-17 | |
US33498701P | 2001-10-23 | 2001-10-23 | |
EP02766022A EP1416965B8 (en) | 2001-08-17 | 2002-08-16 | Assay method for alzheimer's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1107901T1 true CY1107901T1 (el) | 2013-09-04 |
Family
ID=27405654
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20081100267T CY1107901T1 (el) | 2001-08-17 | 2008-03-07 | Μεθοδος προσδιορισμου για ασθενεια alzheimer |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1416965B8 (el) |
JP (2) | JP4511830B2 (el) |
AT (1) | ATE381346T1 (el) |
CA (1) | CA2457145C (el) |
CY (1) | CY1107901T1 (el) |
DE (1) | DE60224200T2 (el) |
DK (1) | DK1416965T3 (el) |
ES (1) | ES2295401T3 (el) |
HK (1) | HK1061960A1 (el) |
PT (1) | PT1416965E (el) |
WO (1) | WO2003015617A2 (el) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101670105B (zh) | 2000-02-24 | 2014-08-06 | 华盛顿大学 | 螯合淀粉样蛋白β肽的人源化抗体 |
DK1944040T3 (da) | 2001-08-17 | 2012-10-29 | Univ Washington | Analysefremgangsmåde for Alzheimers sygdom |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
US7575747B2 (en) | 2003-02-10 | 2009-08-18 | Applied Molecular Evolution | Aβ binding molecules |
EP1480041A1 (en) * | 2003-05-22 | 2004-11-24 | Innogenetics N.V. | Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease |
GB0519398D0 (en) * | 2005-09-23 | 2005-11-02 | Antisoma Plc | Biological materials and uses thereof |
KR20140087058A (ko) | 2005-11-30 | 2014-07-08 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
PT2289909E (pt) | 2005-11-30 | 2015-02-10 | Abbvie Inc | Método de rastreio, processo de purificação de globulómeros a-beta não difundíveis, anticorpos selectivos contra os referidos globulómeros a-beta não difundíveis e processo para o fabrico dos referidos anticorpos |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
CN101981053B (zh) | 2007-01-18 | 2013-11-13 | 伊莱利利公司 | 聚乙二醇化的AβFAB |
US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
WO2010093001A1 (ja) * | 2009-02-13 | 2010-08-19 | 国立大学法人大阪大学 | アルツハイマー病の診断方法および診断薬 |
KR101531949B1 (ko) | 2009-12-11 | 2015-06-26 | 아라클론 바이오테크, 에스.엘. | 아밀로이드 베타 펩티드의 개선된 검출 방법 및 시약 |
ES2684475T3 (es) | 2010-04-15 | 2018-10-03 | Abbvie Inc. | Proteínas que se unen a beta amiloide |
MX358739B (es) | 2010-08-14 | 2018-09-03 | Abbvie Inc Star | Proteinas de union a amiloide beta. |
EP2511296A1 (en) | 2011-04-12 | 2012-10-17 | Araclón Biotech, S. L. | Antibody, kit and method for determination of amyloid peptides |
US20170336395A1 (en) * | 2013-11-20 | 2017-11-23 | University Of Iowa Research Foundation | Methods and compositions for treating amyloid deposits |
CN109187981A (zh) * | 2018-08-01 | 2019-01-11 | 万东山 | 一种快速检测β-淀粉样蛋白的量子点免疫层析试纸条与应用 |
WO2020031116A1 (en) * | 2018-08-08 | 2020-02-13 | Seoul National University R&Db Foundation | Method of diagnosing and treating alzheimer disease using plasma tau level in conjunt ion with beta-amyloid level as diagnostic index |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69334337D1 (de) * | 1992-10-26 | 2010-08-26 | Elan Pharm Inc | Verfahren zur Identifizierung von Hemmstoffverbindungen der Freisetzung von Beta-Amyloidpeptid (BAP) |
TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US6730778B2 (en) * | 1997-12-19 | 2004-05-04 | Pharmacia And Upjohn Company | Human sel-10 polypeptides and polynucleotides that encode them |
CN101670105B (zh) * | 2000-02-24 | 2014-08-06 | 华盛顿大学 | 螯合淀粉样蛋白β肽的人源化抗体 |
-
2002
- 2002-08-16 CA CA2457145A patent/CA2457145C/en not_active Expired - Fee Related
- 2002-08-16 JP JP2003520382A patent/JP4511830B2/ja not_active Expired - Lifetime
- 2002-08-16 ES ES02766022T patent/ES2295401T3/es not_active Expired - Lifetime
- 2002-08-16 DK DK02766022T patent/DK1416965T3/da active
- 2002-08-16 AT AT02766022T patent/ATE381346T1/de active
- 2002-08-16 PT PT02766022T patent/PT1416965E/pt unknown
- 2002-08-16 DE DE60224200T patent/DE60224200T2/de not_active Expired - Lifetime
- 2002-08-16 WO PCT/US2002/026321 patent/WO2003015617A2/en active IP Right Grant
- 2002-08-16 EP EP02766022A patent/EP1416965B8/en not_active Expired - Lifetime
-
2004
- 2004-07-08 HK HK04104992A patent/HK1061960A1/xx not_active IP Right Cessation
-
2008
- 2008-03-07 CY CY20081100267T patent/CY1107901T1/el unknown
-
2009
- 2009-09-09 JP JP2009208372A patent/JP5162553B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO2003015617A3 (en) | 2004-01-29 |
EP1416965A2 (en) | 2004-05-12 |
DE60224200D1 (de) | 2008-01-31 |
ATE381346T1 (de) | 2008-01-15 |
EP1416965B8 (en) | 2008-02-13 |
ES2295401T3 (es) | 2008-04-16 |
JP5162553B2 (ja) | 2013-03-13 |
CA2457145A1 (en) | 2003-02-27 |
JP2010044078A (ja) | 2010-02-25 |
PT1416965E (pt) | 2008-04-01 |
JP4511830B2 (ja) | 2010-07-28 |
EP1416965B1 (en) | 2007-12-19 |
EP1416965A4 (en) | 2005-11-02 |
CA2457145C (en) | 2010-12-21 |
DE60224200T2 (de) | 2008-07-10 |
JP2004538477A (ja) | 2004-12-24 |
DK1416965T3 (da) | 2008-05-05 |
HK1061960A1 (en) | 2004-10-15 |
WO2003015617A2 (en) | 2003-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1107901T1 (el) | Μεθοδος προσδιορισμου για ασθενεια alzheimer | |
EP1944040A3 (en) | Assay method for Alzheimer's disease | |
DK0830170T3 (da) | Automatiseret infusionssystem med dosishastighedsberegner | |
HK1061353A1 (en) | Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays | |
MXPA02011656A (es) | Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos. | |
ATE512224T1 (de) | Rekonstituierter menschlicher anti-hm.1 antikörper | |
EP1238985A4 (en) | HUMAN ANTIBODY FOR TRANSPLANTATION OF A REGION OF DETERMINATION OF COMPLEMENTARITY AGAINST GANGLIOSIDE GD3, AND DERIVATIVES THEREOF | |
ATE108666T1 (de) | Ultraschall-kontrastmittel, verfahren zu ihrer herstellung und verwendung derselben als diagnostika und therapeutika. | |
WO2000018954A3 (en) | Use of pex in the treatment of metabolic bone diseases | |
ES2138729T3 (es) | Metodos de diagnostico de la preeclampsia. | |
ATE234466T1 (de) | Verfahren zur feststellung von antipolymerantikörper und diagnosetestsatz zur feststellung von siliconabhängigen krankheiten | |
EP0674661A4 (en) | TITRATION AND TREATMENT FOR DEMYELINIZING DISEASES SUCH AS MULTIPLE SCLEROSIS. | |
ATE318328T1 (de) | Diagnostika und therapeutika für osteoporose | |
BR0314713A (pt) | Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias | |
BRPI0407213A (pt) | Método de emprego da elevação de marinobufagenina na determinação da presença de pré-eclampsia e aparelhos relacionados | |
EA199700196A1 (ru) | Способ получения фактора ix из биологических источников и фактор ix, полученный этим способом | |
WO2002016636A3 (en) | Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders | |
WO2004003563A3 (en) | Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases | |
WO2004038411A3 (en) | Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases | |
AU4098201A (en) | Method for diagnosing efficacy of xenotypic antibody therapy | |
FR2878852B1 (fr) | Procede de production d'immunoglobulines anti-thymocytes humains | |
WO2003104811A3 (en) | DIAGNOSTIC AND THERAPEUTIC USE OF THE ACUTE STEROIDOGEN RESPONSE REGULATORY PROTEIN FOR TREATING NEURODEGENERATIVE DISEASES | |
WO2002088345A3 (en) | Murine dnasex, medicament containing the same and non-human mammal comprising modified dnasex gene | |
CA2343713A1 (en) | Use of pex in the treatment of metabolic bone diseases | |
FR2837284B1 (fr) | Methode de diagnostic serologique in vitro des endocardites infectieuses |